Compare KULR & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KULR | BDTX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 171.9M |
| IPO Year | 2016 | 2020 |
| Metric | KULR | BDTX |
|---|---|---|
| Price | $3.93 | $1.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 2.0M | ★ 2.3M |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,274,028.00 | N/A |
| Revenue This Year | $123.93 | N/A |
| Revenue Next Year | $63.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.94 | $1.60 |
| 52 Week High | $7.49 | $4.94 |
| Indicator | KULR | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.46 | 48.94 |
| Support Level | $3.48 | $1.60 |
| Resistance Level | $4.40 | $2.30 |
| Average True Range (ATR) | 0.37 | 0.14 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 61.69 | 73.40 |
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices. The Company operated two segments -EMP and Mining of Digital Assets.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.